Abstract
Objectives
To investigate the effect of rosiglitazone, a synthetic selective peroxisome proliferator-activated receptor (PPAR)-γ agonist, for cytokine production and PPAR-γ expression in nasal mucosa.
Methods
Mice in allergic rhinitis group received ovalbumin sensitization followed by ovalbumin intranasal challenge. Mice in the rosiglitazone group received rosiglitazone treatment additionally. Various allergic responses were then assessed.
Results
The frequency of nasal rubs and ovalbumin-specific immunoglobulin E decreased significantly in the rosiglitazone group compared with the allergic rhinitis group. The rosiglitazone group also showed that inflammation was markedly reduced by rosiglitazone administration. Immunohistochemistry showed that PPAR-γ protein expression in nasal mucosa was enhanced in the allergic rhinitis group and the rosiglitazone group compared with control mice.
Conclusion
PPAR-γ activation with rosiglitazone effectively inhibited allergic symptom development, nasal mucosal inflammation, and production of ovoalbumin-specific immunoglobulin E and Th2-type cytokine. Our results provide evidence of the therapeutic potential of PPAR-γ agonist for the treatment of allergic rhinitis.
Get full access to this article
View all access options for this article.